Literature DB >> 20203537

Effects of renin-angiotensin system blockade on islet function in diabetic rats.

L Yuan1, X Li, G-L Xu, C-J Qi.   

Abstract

AIMS: To investigate the effects of renin-angiotensin system (RAS) blockade on islet structure and function in diabetic rats, and its mechanisms.
METHODS: Diabetic rat models were created by high-fat high-caloric laboratory chow plus small dose (30 mg/kg) streptozotocin ip injection. After 8-week intervention with perindopril (AE, no.=10) or valsartan (AR, no.=10), all the animals' islet function was evaluated by iv glucose tolerance test. Pancreases were stained by immunohistochemistry technique to qualitative and/or quantitative analysis the content of insulin, inducible nitric oxide synthase (iNOS), transforming growth factors-beta1 (TGF-beta1) in islets. The apoptosis of islet cells was detected by transferase-mediated dUTP nick-end labeling dUTP nick end labeling (TUNEL). The expression level of angiotensinogen (AGT) and insulin mRNA in islets were detected by RT-PCR.
RESULTS: Compared with normal control group (NC, no.=10), area under the curve of insulin from 0 to 10 min (AUCI0-10) of diabetes group (DM, no.=8) was decreased by 66.9%, the relative expression of local AGT was increased by 69.2%, the insulin relative concentration (IRC) of beta-cell and the expression of insulin mRNA were decreased significantly, the amount of apoptotic cells in unit islet area was increased by 2.1 times, the relative content of iNOS and TGF-beta1 positive cell relative volume (TRV) was increased by 23.0% and 2.52 times, respectively (all p<0.01). Compared with DM group, AUCI0-10 of AE and AR group was increased by 41.4% and 33.2%, respectively; the relative expression of local AGT was decreased by 21.4% and 23.4%, respectively; IRC and the expression of insulin mRNA were increased significantly; the amount of apoptotic islet cells was decreased by 79.0% and 36.2%, respectively; the relative content of iNOS was decreased by 16.5% and 18.9%, respectively; TRV was decreased by 43.8% and 35.6%, respectively (all p<0.01). There were no significant differences between group AE and AR.
CONCLUSION: Blockade of RAS may improve diabetic rats islet function via the amelioration of intra-islets oxidative stress, fibrosis and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20203537     DOI: 10.1007/BF03346544

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  18 in total

Review 1.  Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy.

Authors:  Hernan Rincon-Choles; Balakuntalam S Kasinath; Yves Gorin; Hanna E Abboud
Journal:  Kidney Int Suppl       Date:  2002-12       Impact factor: 10.545

2.  Angiotensin induces inflammatory activation of human vascular smooth muscle cells.

Authors:  R Kranzhöfer; J Schmidt; C A Pfeiffer; S Hagl; P Libby; W Kübler
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-07       Impact factor: 8.311

3.  Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.

Authors:  Hussam Abuissa; Philip G Jones; Steven P Marso; James H O'Keefe
Journal:  J Am Coll Cardiol       Date:  2005-09-06       Impact factor: 24.094

Review 4.  Cytokines and nitric oxide in islet inflammation and diabetes.

Authors:  M L McDaniel; G Kwon; J R Hill; C A Marshall; J A Corbett
Journal:  Proc Soc Exp Biol Med       Date:  1996-01

Review 5.  Oxidative stress and pancreatic beta-cell dysfunction.

Authors:  Hideaki Kaneto; Dan Kawamori; Taka-aki Matsuoka; Yoshitaka Kajimoto; Yoshimitsu Yamasaki
Journal:  Am J Ther       Date:  2005 Nov-Dec       Impact factor: 2.688

Review 6.  Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

Authors:  A J Scheen
Journal:  Diabetes Metab       Date:  2004-12       Impact factor: 6.041

7.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta.

Authors:  José G Abreu; Nan I Ketpura; Bruno Reversade; E M De Robertis
Journal:  Nat Cell Biol       Date:  2002-08       Impact factor: 28.824

9.  Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).

Authors:  Richard Andraws; David L Brown
Journal:  Am J Cardiol       Date:  2007-02-16       Impact factor: 2.778

10.  Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat.

Authors:  Christos Tikellis; Peter J Wookey; Riccardo Candido; Sof Andrikopoulos; Merlin C Thomas; Mark E Cooper
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

View more
  15 in total

1.  Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction.

Authors:  Tatiane M Murça; Tatiane C S Almeida; Mohan K Raizada; Anderson J Ferreira
Journal:  Exp Physiol       Date:  2012-01-27       Impact factor: 2.969

Review 2.  The renin-angiotensin-aldosterone system and glucose homeostasis.

Authors:  James Matthew Luther; Nancy J Brown
Journal:  Trends Pharmacol Sci       Date:  2011-08-29       Impact factor: 14.819

Review 3.  The renin angiotensin aldosterone system and insulin resistance in humans.

Authors:  Patricia C Underwood; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

4.  Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways.

Authors:  H D Long; Y E Lin; M J Liu; L Y Liang; Z H Zeng
Journal:  J Endocrinol Invest       Date:  2013-04-23       Impact factor: 4.256

5.  Ang(1-7) treatment attenuates β-cell dysfunction by improving pancreatic microcirculation in a rat model of Type 2 diabetes.

Authors:  L Yuan; Y Li; G Li; Y Song; X Gong
Journal:  J Endocrinol Invest       Date:  2013-04-30       Impact factor: 4.256

6.  Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats.

Authors:  Long Jin; Sun Woo Lim; Kyoung Chan Doh; Shang Guo Piao; Jian Jin; Seong Beom Heo; Byung Ha Chung; Chul Woo Yang
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

7.  NADPH oxidase inhibition prevents beta cell dysfunction induced by prolonged elevation of oleate in rodents.

Authors:  K Koulajian; T Desai; G C Liu; A Ivovic; J N Patterson; C Tang; J El-Benna; J W Joseph; J W Scholey; A Giacca
Journal:  Diabetologia       Date:  2013-02-21       Impact factor: 10.122

8.  Renin-angiotensin system blockers protect pancreatic islets against diet-induced obesity and insulin resistance in mice.

Authors:  Eliete Dalla Corte Frantz; Camila Crespo-Mascarenhas; Andre Rodrigues C Barreto-Vianna; Marcia Barbosa Aguila; Carlos Alberto Mandarim-de-Lacerda
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

9.  Improved Glucose-Stimulated Insulin Secretion by Selective Intraislet Inhibition of Angiotensin II Type 1 Receptor Expression in Isolated Islets of db/db Mice.

Authors:  Zhen Zhang; Chunyan Liu; Zhenhua Gan; Xinyi Wang; Qiuyan Yi; Yanqing Liu; Yingzhijie Wang; Bin Lu; Hong Du; Jiaqing Shao; Jun Wang
Journal:  Int J Endocrinol       Date:  2013-11-24       Impact factor: 3.257

10.  Expression of CTRP3, a novel adipokine, in rats at different pathogenic stages of type 2 diabetes mellitus and the impacts of GLP-1 receptor agonist on it.

Authors:  Xin Li; Li Jiang; Miao Yang; Yu-wen Wu; Su-xin Sun; Jia-zhong Sun
Journal:  J Diabetes Res       Date:  2014-08-11       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.